NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 19, 2024, for a potential sale of up to 10,000,000 ordinary shares. The shares include 224,697 shares issued as commitment shares to YA II PN, LTD. (YA) under a Standby Equity Purchase Agreement, and up to 9,775,303 additional shares that may be sold to YA over a 36-month period. The agreement allows NeuroSense to sell up to $30 million in ordinary shares to YA, subject to certain limitations. The filing is part of NeuroSense's efforts to raise capital for advancing clinical development of its lead product candidate, PrimeC, for ALS, and for other corporate purposes. The registration statement's effectiveness is pending, and the sale of shares will be subject to market conditions and other factors.

NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 19, 2024, for a potential sale of up to 10,000,000 ordinary shares. The shares include 224,697 shares issued as commitment shares to YA II PN, LTD. (YA) under a Standby Equity Purchase Agreement, and up to 9,775,303 additional shares that may be sold to YA over a 36-month period. The agreement allows NeuroSense to sell up to $30 million in ordinary shares to YA, subject to certain limitations. The filing is part of NeuroSense's efforts to raise capital for advancing clinical development of its lead product candidate, PrimeC, for ALS, and for other corporate purposes. The registration statement's effectiveness is pending, and the sale of shares will be subject to market conditions and other factors.